Detailed answers about MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED, including incorporation, status, business activity, and accounts information.
When was MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED founded?
MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED was officially incorporated on 27 March 2019 and is registered under company number 11909308. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED?
MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED do?
MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED operates in the following sector: 86210 - General medical practice activities. This provides insight into the company's primary business activity and industry focus.
What is MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED's registered address?
The registered office address of MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED is C/O FORVIS MAZARS LLP ONE, ST PETER'S SQUARE, MANCHESTER, UNITED KINGDOM, M2 3DE. This is the official address filed with Companies House for legal and statutory correspondence.
Is MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED financially stable?
The most recent accounts for MANCHESTER ENDOCRINOLOGY & DIABETES LIMITED were made up to 31 March 2025, filed as MICRO ENTITY. Next accounts are due by 31 December 2026.